BioWorld

May 19, 2005

View Archived Issues

Zelos' Series B Round Nets $42M For PTH Drug Pipeline

Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today) Read More

McClellan Plans Use Of CMS Data To Help Monitor Drugs

Read More

Medical Risks, Psychology Fuel Continuing Resistance To tPA

Read More

Avant Sells Rotarix Royalties In Deal Totaling Up To $61M

Read More

News From ASCO

Read More

Other News To Note

Read More